Tulasi Healthcare Introduces Innovative dTMS Therapy for Treatment-Resistant Depression

Tulasi Healthcare, a mental well-being platform, has recently launched its Deep Transcranial Magnetic Stimulation (dTMS) therapy service, targeting individuals grappling with treatment-resistant depression (TRD). 

The therapy offers hope and relief from symptoms, utilising non-invasive brain stimulation techniques authorised by regulatory bodies including the US Food and Drug Administration (FDA) for TRD treatment.

dTMS, an endorsed non-invasive brain stimulation method, holds FDA approval for addressing depression, particularly in individuals with TRD. This type of depression remains unresponsive to conventional treatments, such as psychotherapy and antidepressant medications. 

The therapy involves delivering repetitive magnetic pulses to targeted brain regions, inducing neuroplastic changes that amplify neural circuit connectivity and mood regulation. With encouraging outcomes in treatment-resistant OCD and depression, this advanced transcranial magnetic stimulation (TMS) is gaining prominence.

Dr. Gorav Gupta, cofounder of Tulasi Healthcare and Emoneeds, stated, "We are thrilled to extend a transformative solution to those battling treatment-resistant depression, a challenge many have faced. With our non-invasive brain stimulation technique authorized by regulatory entities, we are resolute in offering an effective route to recovery. Our team of skilled psychiatrists and clinical psychologists are committed to delivering empathetic care and individualized treatment strategies, ensuring each patient receives the necessary support to overcome TRD and achieve enduring mental well-being."

Responses to dTMS may vary, with some experiencing alleviated depressive symptoms within weeks, while others might require a longer duration to observe substantial changes. 

Tulasi Healthcare's comprehensive approach integrates dTMS with other modalities, such as antidepressant medications and psychotherapy, tailored to each patient's unique needs and treatment objectives. The platform aims to provide holistic and personalised treatment by synergising multiple therapies and optimising prospects for successful recovery.

Since its debut in July 2023, Tulasi Healthcare has effectively assisted four patients with treatment-resistant depression. The platform aspires to expand its reach, planning to accommodate up to 50 patients per month. 

Each dTMS session, lasting 20 to 30 minutes, might vary in frequency based on the prescribed treatment protocol, from 4-6 weeks to 12 weeks in some cases. By providing treatment-resistant depression patients with dTMS therapy, Tulasi Healthcare adds dTMS therapy to its repertoire.

Back in June 2023, Sunshine by LISSUN, the leading provider of mental health solutions in India, opened its first offline centre for children with developmental and behavioural challenges. It offers innovative amenities such as counselling chambers, occupational therapy rooms, and assessment zones.